Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Early pregnancy blood pressure patterns tied to hypertension risk years later
Researchers show certain blood pressure patterns during the first 20 weeks of pregnancy were more likely to develop into hypertension later in life.
Heart Rhythm Society legislative advocacy group raising funds for electrophysiology
This week, Heart Rhythm Advocates announced its establishment and called on cardiologists and EPs to support its efforts with membership and joining committees to guide efforts.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.

Gout drug colchicine makes waves as potential CV therapy

Results of the late-breaking COLCOT trial, which explored the efficacy of low-dose colchicine in reducing CV risk in heart attack patients, were a highlight of the American Heart Association’s 2019 Scientific Sessions this month in Philadelphia.

ISCHEMIA: Invasive therapy no better than meds for reducing CV events

People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.

FDA advisors support expanded indication for icosapent ethyl

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted unanimously Nov. 14 to recommend an expanded indication for icosapent ethyl, a purified omega-3 product designed to help heart patients keep their lipid levels in check.

NIH allocates minimal funding to cardiac arrest research

Research that will be presented at the American Heart Association’s Resuscitation Science Symposium in Philadelphia this month suggests the National Institutes of Health invests far less money in cardiac arrest research than in research for other conditions, including diabetes, drug-use disorders and ischemic heart disease.

Young marijuana users face increased risk of stroke

Young people who use cannabis—especially if they’re frequent users—could face an up to threefold increased risk of stroke compared to their peers, researchers have found.

AI tool predicts HF mortality with 88% accuracy

A collaboration between physicists and cardiologists at the University of California San Diego has resulted in an AI tool that can predict heart failure patients’ life expectancy with 88% accuracy.

Taller people at greater risk for AFib

Taller people might be at an increased risk for atrial fibrillation, according to research set for presentation at the American Heart Association’s Scientific Sessions on Nov. 16.

Insomnia linked to higher odds of CVD, stroke

Research out of Peking University in Beijing, China, has established a link between insomnia and heart disease, ABC News reports.

Clinical

Early pregnancy blood pressure patterns tied to hypertension risk years later

Heart Rhythm Society legislative advocacy group raising funds for electrophysiology

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure